Ligand announces new topiramate injection data

Ligand Pharmaceuticals Incorporated presented new data on Captisol-enabled Topiramate Injection, a potential replacement therapy for the treatment of certain emergent neurological conditions, including epilepsy, when oral administration is not feasible. The poster was featured at the 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference in London, England. The authors presented modeling and simulations of IV topiramate dosing based on previous studies conducted by UMN faculty in healthy research participants and patients. In addition, preliminary pharmacokinetic data was presented from 25 healthy participants in a CURx ongoing randomized, single-center, open-label, cross-over clinical study for an investigational intravenous formulation of topiramate, an antiseizure and anti-migraine medication.